| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly is making significant strides in product development, particularly with the recent FDA approval of Omvoh for ulcerative colitis and the introduction of innovative weight-loss medications such as Mounjaro and Zepbound. Their focus on health-related breakthroughs and expansion into retail healthcare indicates a strong commitment to improving patient access and care. The demand for their weight-loss drugs is driving exceptional sales growth and positioning the company favorably in the market. Overall, Eli Lilly's emphasis on innovation and successful product launches highlights their leadership in the pharmaceutical industry. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.5 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.7, and the negative at -0.2 on 2025-10-31. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (4.4) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-31 | 0%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.5 | |||||||
| 2025-10-30 | 1%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.8 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | 7 | |||||||
| 2025-10-28 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | 5.5 | |||||||
| 2025-10-27 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| 2025-10-26 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| 2025-10-25 | 0%(0%) | 0 | 0% | 0.4 | 3.4 | -1 | |||||||
| 2025-10-24 | 0%(0%) | 0 | 0% | 0.5 | 3.9 | 6 | |||||||
| 2025-10-23 | 0%(0%) | 0 | 0% | 0.3 | 2.8 | -1 | |||||||
| 2025-10-22 | 0%(0%) | 0 | 0% | 0.2 | 2.4 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-10-31 17:01:57 The substantial financial activity in the obesity and diabetes sector reflects broader investment trends and potential for continued growth. |
| 2025-10-31 17:01:57 Eli Lilly's drug pipeline, particularly in diabetes and obesity treatments, showcases strong product development and future growth opportunities. |
| 2025-10-31 17:01:57 Positive earnings reports have led to an increase in stock performance for Eli Lilly, with significant potential upside noted by analysts. |
| 2025-10-31 17:01:57 The competitive landscape for obesity and diabetes treatments is intensifying, highlighted by Eli Lilly's market performance and bidding wars among drugmakers. |
| 2025-10-31 17:01:57 Eli Lilly's robust quarterly results and positive guidance indicate strong earnings potential. |
| 2025-10-31 15:48:23 Analysts boosting price targets based on the company's performance indicates strong market confidence. |
| 2025-10-31 15:48:23 The rising momentum of Eli Lilly's obesity drug contributes to their revenue growth and market position. |
| 2025-10-31 15:48:23 Eli Lilly's significant revenue increase and earnings surpassing estimates indicate strong financial performance. |
| 2025-10-31 13:48:08 The article emphasizes the expectation of market demand for Eli Lilly's upcoming weight-loss drug, indicating a positive outlook. |
| 2025-10-31 13:48:08 Eli Lilly's proactive approach to producing weight-loss pills ahead of regulatory approval highlights their readiness for market entry. |